Is SPHDF or JNJ a better dividend investment in 2026?

SPHDF currently yields 10.20% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: SPHDF offers higher current income.

What is the dividend yield difference between SPHDF and JNJ?

SPHDF has a forward dividend yield of 10.20% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 6.84 percentage points.

Home › Compare › SPHDF vs JNJ

SPHDF vs JNJ: Dividend Comparison 2026

SPHDF yields 10.20% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SPHDF wins by $19.3K in total portfolio value

INVESTMENT

TIME HORIZON10 years

SPHDF

● Live price

10.20%

Share price

$19.60

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$39.3K

Annual income

$1,936.67

Full SPHDF calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — SPHDF vs JNJ

📍 SPHDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SPHDF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SPHDF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SPHDF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHDF

Annual income on $10K today (after 15% tax)

$867.35/yr

After 10yr DRIP, annual income (after tax)

$1,646.17/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, SPHDF beats the other by $942.56/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHDF + JNJ for your $10,000?

SPHDF: 50%JNJ: 50%

100% JNJ50/50100% SPHDF

Portfolio after 10yr

$29.6K

Annual income

$1,382.22/yr

Blended yield

4.66%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SPHDF

No analyst data

Altman Z

-3.9

Piotroski

4/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHDF buys

JNJ buys

No recent congressional trades found for SPHDF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSPHDFJNJ

Forward yield	10.20% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$39.3K ✓	$20.0K
Annual income after 10y	$1,936.67 ✓	$827.78
Total dividends collected	$14.8K ✓	$5.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: SPHDF vs JNJ ($10,000, DRIP)

Year	SPHDF Portfolio	SPHDF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$11,720	$1,020.41	$10,676	$355.77	+$1.0K → SPHDF
2	$13,659	$1,117.72	$11,407	$389.39	+$2.3K → SPHDF
3	$15,832	$1,217.34	$12,198	$426.53	+$3.6K → SPHDF
4	$18,259	$1,318.74	$13,056	$467.62	+$5.2K → SPHDF
5	$20,958	$1,421.40	$13,987	$513.12	+$7.0K → SPHDF
6	$23,950	$1,524.81	$14,998	$563.56	+$9.0K → SPHDF
7	$27,255	$1,628.49	$16,098	$619.52	+$11.2K → SPHDF
8	$30,895	$1,731.97	$17,295	$681.69	+$13.6K → SPHDF
9	$34,893	$1,834.83	$18,599	$750.82	+$16.3K → SPHDF
10	$39,272	$1,936.67	$20,022	$827.78	+$19.3K → SPHDF

SPHDF vs JNJ: Complete Analysis 2026

SPHDF — Stock

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Full SPHDF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this SPHDF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHDF vs SCHD SPHDF vs JEPI SPHDF vs O SPHDF vs KO SPHDF vs MAIN SPHDF vs ABBV SPHDF vs MRK SPHDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.